{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:23:09Z","timestamp":1782786189503,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clml.2018.11.009","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T22:26:21Z","timestamp":1542061581000},"page":"116-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic Utility of the IPS 3 Score for Predicting Outcomes in Advanced Hodgkin Lymphoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Prasanth","family":"Ganesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manikandan","family":"Dhanushkodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trivadi S.","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnarathinam","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Sundersingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenali Gnana","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.11.009_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.009_bib2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.009_bib3","first-page":"1545","article-title":"ABVD versus BEACOPP for Hodgkin lymphoma","volume":"365","author":"Borchmann","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.009_bib4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdv077","article-title":"Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin lymphoma","volume":"26","author":"Ganesan","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.11.009_bib5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin for stage III or IV Hodgkin lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.009_bib6","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin disease. International Prognostic Factors Project on Advanced Hodgkin Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.009_bib7","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International prognostic score in advanced-stage Hodgkin lymphoma: altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.009_bib8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.13634","article-title":"Evaluation of the international prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced Hodgkin lymphoma in the modern era","volume":"171","author":"Diefenbach","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.11.009_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/0971-5851.171550","article-title":"Clinical profile and outcome of adult Hodgkin lymphoma: experience from a tertiary care institution","volume":"36","author":"Maddi","year":"2015","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2018.11.009_bib10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00277-011-1262-8","article-title":"Hodgkin lymphoma--long-term outcome: an experience from a tertiary care cancer center in North India","volume":"90","author":"Ganesan","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.11.009_bib11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.009_bib12","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.009_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00259-007-0506-2","article-title":"Staging with PET and the \u201cWill Rogers\u201d effect: redefining prognosis and survival in patients with cancer","volume":"35","author":"Basu","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:49Z","timestamp":1761870709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018311273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2152265018311273"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Utility of the IPS 3 Score for Predicting Outcomes in Advanced Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}